The global mRNA cancer-vaccine market is forecast to grow from roughly $1.8 billion in 2024 to nearly $7.3 billion by 2030. This expansion reflects a compound annual growth rate of more than 25%, driven largely by personalized treatments for lung cancer.

Broader estimates for the entire mRNA cancer vaccines and therapeutics sector are significantly higher. One projection places this larger market at approximately $71.2 billion in 2025, rising to $141.5 billion by 2030. These figures highlight the potential scale if personalized mRNA vaccines become standard care alongside existing immunotherapies.

Market Projections

Lung cancer represents a primary opportunity within this landscape. Treatment strategies increasingly combine personalized vaccines with checkpoint inhibitors, genetic testing, and other precision-medicine tools. The broader global mRNA therapeutics market is also expected to expand from about $11.7 billion in 2023 to roughly $31.3 billion by 2030.

Company Developments

Sunshine Biopharma Inc. (NASDAQ: SBFM) reported in vivo tumor suppression with its K1.1 mRNA lipid nanoparticle program. The company aims to pair K1.1 mRNA with a cancer vaccine targeting associated antigens in non-small cell lung cancer (NSCLC). This dual therapy approach seeks to transform "cold" tumors into "hot" tumors while suppressing growth.

BioNTech SE (NASDAQ: BNTX) will present new clinical data from its lung cancer treatment pipeline at the International Association for the Study of Lung Cancer World Conference in Seoul from September 12-15, 2026. The data covers assets including pumitamig and gotistobart, as well as a novel combination trial with an antibody-drug conjugate.

AstraZeneca PLC (NYSE: AZN) and Daiichi Sankyo’s Enhertu demonstrated statistically significant improvement in progression-free survival in the DESTINY-Lung04 Phase III trial. It is the first HER2-directed medicine to show such improvement over standard care in patients with HER2-mutant advanced NSCLC.

Moderna, Inc. (NASDAQ: MRNA) announced the dosing of the first U.S. participant in its Phase 1 study for mRNA-4200. This tumor-targeted cancer antigen therapy encodes seven antigens shared across patients and tumor types to induce T-cell responses.

Bristol Myers Squibb (NYSE: BMY) received FDA approval for ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone for multiple myeloma. ZENBEXUS is the first FDA-approved cereblon-modulating protein degrader (CELMoD).

What the Numbers Show

The divergence between the narrow mRNA cancer vaccine forecast ($7.3 billion by 2030) and the broader therapeutics estimate ($141.5 billion by 2030) underscores that current valuation models rely heavily on the successful integration of mRNA technology into wider therapeutic platforms beyond standalone vaccines.

Sunshine Biopharma Inc. (NASDAQ: SBFM) announced on Wednesday that it has secured regulatory approval to introduce its generic Enalapril tablets across the Canadian market. The newly approved medication, the generic equivalent of the brand Vasotec, will be available in multiple dosage strengths: 2.5mg, 5mg, 10mg, and 20mg tablets. This approval signals a significant strategic step into first-line antihypertensive treatments.

Enalapril belongs to the class of medications known as ACE (Angiotensin-Converting Enzyme) inhibitors. These drugs work by relaxing blood vessels to improve blood flow and heart efficiency. The medication is widely prescribed to lower high blood pressure, reduce the risk of stroke and heart attack, and improve survival rates in patients with heart failure.

Market Context

The approval aligns with broader growth trends in the cardiovascular sector. According to BioSpace, the global anti-hypertensive drug market was valued at $25.94 billion in 2025 and is projected to reach $37.24 billion by 2034, expanding at a compound annual growth rate (CAGR) of 4.1%.

Canada represents a significant opportunity within this landscape, accounting for approximately 2.1% of the global pharmaceutical market and ranking as the sixth largest worldwide, according to IQVIA Pharmafocus 2028.

Distribution Strategy

Sunshine Biopharma will leverage its wholly owned Canadian subsidiary, Nora Pharma Inc., to distribute the new product. The company has established a robust distribution network across Canada, positioning it to capitalize on the demand for first-line hypertension therapies as soon as production is ready. Retail pharmacies across Canada can expect to receive their initial shipments of the newly approved generic medication by the close of 2026.

"With the introduction of Enalapril oral tablets, we're continuing to build a portfolio that delivers real impact," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "Enalapril is essential in managing hypertension and heart failure, and this launch enhances access to dependable, cost‑effective cardiovascular treatment for patients who need it most."

Company Portfolio Update

Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In May, the company received Canadian regulatory approval for generic amoxicillin as part of the expansion of its generic antibiotic portfolio. That product is expected to be ready to ship to pharmacies in August 2026.

In addition, the company is conducting a proprietary drug development program which includes K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections.

In June, the company concluded a one-for-ten reverse stock split to regain compliance with Nasdaq’s minimum bid price requirement for continued listing. Shares were up 1.79% at $1.13 during premarket trading on Wednesday.